<DOC>
	<DOCNO>NCT00088959</DOCNO>
	<brief_summary>This phase I trial study side effect best dose celecoxib give together erlotinib treat former smoker stage IIIB , stage IV , recurrent , progressive non-small cell lung cancer . Celecoxib erlotinib may stop growth tumor cell block enzymes necessary growth .</brief_summary>
	<brief_title>Celecoxib Erlotinib Treating Former Smokers With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To estimate clinical toxicity tolerability erlotinib combine celecoxib patient advance non-small cell lung cancer ( NSCLC ) . SECONDARY OBJECTIVES : I . To estimate tumor response rate erlotinib combine celecoxib patient advance NSCLC . II . To estimate dose celecoxib result maximal induction apoptosis , maximal inhibition prostaglandin E2 ( PGE2 ) bronchoalveolar ( BAL ) fluid , maximal inhibition bronchial cell proliferation combine erlotinib . III . To estimate effect erlotinib combination erlotinib celecoxib bronchial expression COX-2 . IV . To estimate effect erlotinib combination erlotinib ( celecoxib autophosphorylation epidermal growth factor receptor ( EGFR ) skin endobronchial biopsy . V. To estimate degree correlation autophosphorylation EGFR skin endobronchial sample . TERTIARY OBJECTIVES : I . To estimate effect combination erlotinib COX-2 inhibitor ( celecoxib ) frequency fractional allelic loss ( FAL ) endobronchial biopsy , metaplasia dysplasia endobronchial biopsy , endobronchial proliferation . OUTLINE : This open-label , dose-escalation study celecoxib . Patients receive oral erlotinib hydrochloride daily oral celecoxib twice daily . Treatment continue absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos celecoxib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 6 additional patient treat MTD . Patients follow 4 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Criteria : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) meet 1 follow stage criterion : Stage IIIB pleural effusion ; Stage IV disease ; recurrent progressive disease prior surgery , radiotherapy , and/or chemotherapy If sole prior treatment adjuvant neoadjuvant setting , tumor progression recurrence must occur within 6 month completion prior treatment Absolute neutrophil count &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 10 g/dL Hemostasis normal Creatinine = &lt; 2.0 mg/dL No significant cardiovascular disease No New York Heart Association class III IV cardiac disease No uncontrolled dysrhythmia No unstable angina No myocardial infarction within past 6 month FEV1 &gt; = 1.0 liter OR 40 % predict within past 3 month Oxygen saturation &gt; = 90 % room air Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study treatment Willing undergo bronchoscopy No allergy sulfonamide hypersensitivity reaction celecoxib No medical psychological condition ( e.g. , acute psychosis ) would preclude study participation At least 4 week since prior chemotherapy ( 6 week mitomycin ) At least 4 week since prior radiotherapy Prior complete resection allow provide histologic cytologic documentation disease recurrence More 3 month since prior chemopreventative agent ( e.g. , oltipraz , retinoids , Nacetylcysteine [ NAC ] ) No prior erlotinib hydrochloride No prior EGFR antagonists No concurrent medication know interact erlotinib hydrochloride celecoxib , include follow : Fluconazole , Lithium , Furosemide , Angiotensinconverting enzyme inhibitor , Phenytoin , Carbamazepine , Rifampin , Barbiturates , Hypericum perforatum ( St. John 's wort ) No concurrent nonsteroidal antiinflammatory drug Concurrent aspirin average dose 325 mg/day allow No aspirin treatment 7 day prior bronchoscopic skin biopsy No concurrent EGFR inhibitor cyclooxygenase2 ( COX2 ) inhibitor Meets 1 follow criterion : 1 ) Advanced NSCLC least stable disease &gt; = 4 course platinumcontaining chemotherapy 2 ) Relapsed refractory disease treatment &gt; = 1 prior platinumcontaining chemotherapy program , include adjuvant neoadjuvant therapy NSCLC No untreated brain metastasis ECOG 01 Former smoker , indicate following : 1 ) At least 30 packyear smoke history 2 ) Smoking duration least 10 year 3 ) At least 12 month selfreported smoke cessation 4 ) Negative urine cotinine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>